Medtronic Acquires HeartWare for $1.1 Billion

| Printer friendly version



Medtronic PLC has announced it has agreed to acquire HeartWare International Inc. for $1.1 billion in cash.  According to the press release, the acquisition will expand Medtronic’s portfolio of diagnostic tools and treatments for heart failure.  The companies have said that they expect the deal to close during Medtronic’s second fiscal quarter, ending in late October.

HeartWare, a firm based in suburban Boston, creates minimally-invasive circulatory support technologies for the treatment of advanced heart failure. The HVAD® System, HeartWare’s flagship product, is the first and most widely studied centrifugal ventricular assist device (VAD), designed to facilitate the heart’s blood-pumping function.  According to the HeartWare website, the HVAD System is the world’s smallest VAD, weighing only 160 grams, allowing for a less invasive implantation procedure and resulting in improved patient recovery times and outcomes.

Doug Godshall, HeartWare’s president and chief executive, said in a statement that the deal gives HeartWare “a unique opportunity to enhance growth in the mechanical circulatory support market.” Mike Coyle, executive vice president and president of the Cardiac and Vascular Group at Medtronic, stated:

“The team at HeartWare has established excellent relationships with its hospital customers and built a strong position and reputation in the marketplace.”

Medtronic estimates that the global VAD market is about $800 million now and is expected to grow by a percentage in the mid-to-high single digits in the current year and accelerate to a percentage in the high-single, low-double digits in the future.

Medtronic said that it did not expect to adjust its fiscal year 2017 revenue outlook or earnings as a result of the acquisition, and that it expected the deal to contribute to earnings in year three.

HeartWare is one of the two major VAD makers to be acquired within the last 12 months. Thoratec was acquired by St. Jude Medical for about $3.3 billion in October 2015. Abbott in turn agreed to acquire St. Jude for $25 billion in April of this year.


Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.